Novocure's presence at the SNO Annual Meeting will include medical booths, sponsored symposia and scientific presentations spanning preclinical, clinical and real-world outcomes research underscoring the safety and efficacy of TTFields therapy, as well as patient and healthcare provider satisfaction with the therapy.
'The SNO Annual Meeting is the largest annual conference focused on neuro-oncology and an ideal forum for sharing new data on the use of immunotherapy and TTFields therapy in the treatment of GBM as well as our largest real-world study to date and additional insights about the safety and efficacy of TTFields therapy,' said
Highlights include: an oral presentation of data from the 2-THE-TOP trial, suggesting TTFields therapy had an enhanced effect with pembrolizumab in patients with newly diagnosed GBM. 2-THE-TOP is an investigator-sponsored phase 2 clinical trial of TTFields therapy plus pembrolizumab plus maintenance temozolomide. an oral presentation of the final results of Novocure's largest non-interventional real-world evidence study to date, the TTFields in
Novocure is also sponsoring an Independent Supported Session, titled Tumor Treating Fields vs. GBM -The Evidence and Experience, on
A CME/Industry Sponsored Symposium, PeerView Live at SNO 2023, Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches (in collaboration with the
The 2023 SNO Annual Meeting will also mark the debut of Novocure's new Optune Gio brand. Optune, Novocure's FDA-approved treatment for newly diagnosed and recurrent GBM, will be renamed Optune Gio on
Presentations include: Final efficacy and correlative analyses of 2-THE-TOP: A pilot study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide in patients with newly diagnosed glioblastoma (ndGBM). Presenter:
Treatment decision and quality of life of patients with newly diagnosed glioblastoma (ndGBM) receiving Tumor Treating Fields (TTFields) therapy in routine clinical care: First results of the TIGER study. Presenter:
Demographics, prescribing patterns, and satisfaction of healthcare professionals who prescribe Tumor Treating Fields (TTFields) therapy to patients with glioblastoma. Presenter:
Tumor Treating Fields (TTFields) therapy in glioblastoma (GBM): relationship between patient experience, global region, and age. Presenter: Eleni T. Batzianouli.
Long-term global post-marketing surveillance data from pediatric, adult and elderly patients with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy. Presenter:
Real world experience with TTFields with emphasis on therapy compliance. Presenter:
Prolonged follow-up of an oligodendroglioma patient with history of Tumor Treating Fields (TTF) as post chemo-radiation maintenance therapy. Presenter:
Distant progression to the posterior fossa in supratentorial glioblastoma: A report of three cases during Tumor Treating Fields therapy. Presenter: Juri Kiyowaka.
Advanced MRI Biomarkers Predict Early Response to Tumor Treating Fields in Glioblastoma. Presenter:
Investigating safety and efficacy of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma - first results of the PriCoTTF phase I/II trial. Presenter:
The pivotal METIS (EF-25) study of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC) following radiosurgery. Presenter:
The pivotal TRIDENT study of Tumor Treating Fields (TTFields) therapy with chemoradiation, followed by maintenance TTFields therapy/temozolomide (TMZ), in newly diagnosed glioblastoma (ndGBM). Presenter:
Adopting Tumor Treating Fields (TTFields) therapy for glioblastoma and other solid cancers: challenges and opportunities. Presenter:
Tumor Treating Fields: Real-World Survival and Quality of Life Outcomes on the XCELSIOR Platform. Presenter:
Development of Tumor Treating Fields (TTFields) arrays for treatment of head tumors in mice models. Presenter:
Molecular characterization of glioma tissue after TTFields treatment. Presenter: Christian Mawrin.
Dielectric properties of intracranial tumors - role of myelin content. Presenter:
ABOUT TUMOR TREATING FIELDS THERAPY
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. The multiple, distinct mechanisms of TTFields therapy work together to selectively target and kill cancer cells. Due to its multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors.
ABOUT OPTUNE
Optune is a noninvasive, antimitotic cancer treatment for glioblastoma (GBM). Optune delivers Tumor Treating Fields (TTFields) therapy to the region of the tumor.
TTFields therapy uses electric fields to disrupt cell division. TTFields therapy does not stimulate or heat tissue and targets dividing cancer cells of a specific size. TTFields therapy takes advantage of the special characteristics and geometrical shape of dividing cells, which make them susceptible to the effects of the alternating electric fields. TTFields therapy causes minimal damage to healthy cells. Mild to moderate skin irritation is the most common side effect reported. TTFields therapy is approved in certain countries for the treatment of adults with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma, some of the most difficult cancer types to treat. The therapy shows promise in multiple solid tumor types - including some of the most aggressive forms of cancer.
ABOUT NOVOCURE
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Headquartered in Root,
FORWARD-LOOKING STATEMENTS
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as 'anticipate,' 'estimate,' 'expect,' 'project,' 'intend,' 'plan,' 'believe' or other words and terms of similar meaning. Novocure's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on
Contact:
Email: investorinfo@novocure.com
Tel: 610-723-7427
Email: media@novocure.com
Tel: 610-723-7428
(C) 2023 Electronic News Publishing, source